Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation - Archive ouverte HAL Access content directly
Journal Articles Clinical Nuclear Medicine Year : 2021

Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation

(1) , (2, 1) , (1) , (1) , (2, 1)
1
2

Abstract

Radiopharmaceutical extravasation is a known nuclear medicine adverse effect, mostly with no complication in case of diagnostic radiopharmaceutical. However, a therapeutic radiopharmaceutical extravasation may have clinical consequences and must be treated quickly and effectively. We report here a case of 177Lu-DOTA0-Tyr3-octreotate extravasation.
Not file

Dates and versions

inserm-03540776 , version 1 (24-01-2022)

Identifiers

Cite

Bruno Maucherat, Nicolas Varmenot, Vincent Fleury, Helene Senellart, Caroline Rousseau. Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation. Clinical Nuclear Medicine, 2021, 46 (2), pp.144-145. ⟨10.1097/RLU.0000000000003452⟩. ⟨inserm-03540776⟩
11 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More